Rapid fecal cytokeratin-19 test and fecal occult blood test in screening for gastrointestinal diseases

Annals of Clinical and Laboratory Science

Volumn 36, Issue 3, 2006, Pages 294-298

  Kim, Hyunjung ^a   Kim, Yonggoo ^a   Yoon, Sangsoon ^b   Lim, Jihyang ^a   Kim, Myungshin ^a   Lee, Soonwook ^a   Kang, Sunghan ^a   Lee, Eun Jung ^a   Kang, Chang Suk ^a   Han, Kyungja ^a  

^a The Catholic University of Korea College of Medicine   (South Korea)

^b Dinona Inc   (South Korea)

Author keywords

Bone marrow transplantation; Childhood diarrhea; Fecal cytokeratin 19; Fecal occult blood; GI cancer; GI inflammation; Graft vs host disease

Indexed keywords

CYTOKERATIN 19;

ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CHILDHOOD DISEASE; CHROMATOGRAPHY; CONTROLLED STUDY; DESQUAMATION; DEVICE; DIAGNOSTIC VALUE; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DIGESTIVE SYSTEM CANCER; DIGESTIVE SYSTEM INFLAMMATION; GASTROINTESTINAL DISEASE; GOLD IMMUNOCHROMATOGRAPHY; HUMAN; IMMUNOCHROMATOGRAPHY; INTESTINE EPITHELIUM; MAJOR CLINICAL STUDY; OCCULT BLOOD TEST; PRIORITY JOURNAL; SCREENING TEST; SENSITIVITY AND SPECIFICITY;

ADULT; CHILD; FECES; GASTROINTESTINAL DISEASES; HUMANS; KERATIN-19; MASS SCREENING; OCCULT BLOOD; TUMOR MARKERS, BIOLOGICAL;

EID: 33748273739     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Lambert R. An overview of the epidemiology and prevention of digestive cancer. World Gastroenterol News 2003;8:21-25.
2. Wilmink AB. Overview of the epidemiology of colorectal cancer. Dis Colon Rectum 1997;40:483-493.
3. Wang HZ, Huang XF, Wang Y, Ji JF, Gu J. Clinical features, diagnosis, treatment and prognosis of multiple primary colorectal carcinoma. World J Gastroenterol 2004;10:2136-2139.
4. Winawer SJ, Fletcher RH, Miller L, Godlee F, Stolar MH, Mulrow CD, Woolf SH, Glick SN, Ganiats TG, Bond JH, Rosen L, Zapka JG, Olsen SJ, Giardiello FM, Sisk JE, van Antwerp R, Brown-Davis C, Marciniak DA, Mayer RJ. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
5. Blum HE. Future population screening for early colorectal cancer. Eur J Cancer 1995;31:1369-1372.
6. Helm JF, Russo MW, Biddle AK, Simpson KN, Ransohoff DF, Sandler RS. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing. Am J Gastroenterol 2000;95:3250-3258.
7. Ransohoff DF, Sandler RS. Clinical practice: screening for colorectal cancer. NEJM 2002;346:40-44.
8. Bruzzi JF, Brennan DD, Fenlon HM. Screening for colorectal cancer. NEJM 2002;346:1672-1674.
9. Laghi A, Iannaccone R, Carbone I, Catalano C, Di Giulio E, Schillaci A, Passariello R. Detection of colorectal lesions with virtual computed tomographic colonography. Am J Surg 2002;183:124-131.
10. Nilsson O, Johansson C, Glimelius B, Persson B, Norgaard-Pedersen B, Andren-Sandberg A, Lindholm L. Sensitivity and specificity of CA242 in gastrointestinal cancer. A comparison with CEA, CA50 and CA 19-9. Br J Cancer 1992;65:215-221.
11. van der Schouw YT, Verbeek AL, Wobbes T, Segers MF, Thomas CM. Comparison of four serum tumour markers in the diagnosis of colorectal carcinoma. Br J Cancer 1992;66:148-154.
12. Eskelinen M, Fasanen P, Kulju A, Janatuinen E, Miettinen P, Poikolainen E, Tarvainen R, Nuutinen P, Paakkonen M, Alhava E. Clinical evaluation of serum tumour markers CEA, CA 50 and CA 242 in colorectal cancer. Anticancer Res 1994;14:1427-1432.
13. Oh SH, Choi JC, Park TS, Kim HH, Lee EY, Kim HY, Sol MY. Serum anti-P53 antibodies and P53 protein expression and their prognostic relevance in patients with gastric cancer. Korean J Lab Med 2004;24:15-21.
14. Ross WA, Douriel D. Colonic graft-versus-host disease. Curr Opin Gastroenterol 2005;21:64-69.
15. Miettinen M. Keratin immunohistochemistry. Update of applications and pitfalls. Pathol Annu 1993;28:113-143.
16. Rosai J. Special techniques in surgical pathology. In: Rosai and Ackerman's Surgical Pathology, 2nd ed., Mosby, Philadelphia, 2004; vol 1, p 55.
17. Correale M, Arnberg H, Blockx P, Bombardieri E, Castelli M, Encabo G, Gion M, Klapdor R, Martin M, Nilsson S. Clinical profile of a new monoclonal antibody-based immunoassay for tissue polypeptide antigen. Int J Biol Markers 1994;9:231-238.
18. Plebani M, De Paoli M, Basso D, Roveroni G, Giacomini A, Galeotti F, Corsini A. Serum tumor markers in colorectal cancer staging, grading, and follow-up. J Surg Oncol 1996;62:239-244.
19. Albaugh GP, Iyengar V, Lohani A, Malayeri M, Bala S, Nair PP. Isolation of exfoliated colonic epithelial cells, a novel, non-invasive approach to the study of cellular markers. Int J Cancer 1992;52:347-350.
20. Ahlquist DA, Wieand HS, Moertel CG, McGill DB, Loprinzi CL, O'Connell MJ, Mailliard JA, Gerstner JB, Pandya K, Ellefson RD. Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests. JAMA 1993;269:1262-1267.
21. Fernandes LC, Kim SB, Matos D. Cytokeratins and carcinoembryonic antigen in diagnosis, staging and prognosis of colorectal adenocarcinoma. World J Gastroenterol 2005;11:645-648.
22. Gratwohl A, Hermans J, Apperley J, et al. Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia. Blood 1995;86:813-818.
23. Champlin RE, Schmitz N, Horowitz MM, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogenic transplantation. Blood 2000;95:3702-3709.
24. Remberger M, Persson U, Hausenberger D, et al. An association between human leukocyte antigen alleles and acute and chronic graft-versus-host disease after allogenic haemopoietic stem cell transplantation. Br J Haematol 2002;119:751-759.
25. Ponec RJ, Hackman RC, McDonald GB. Endoscopic and histologic diagnosis of intestinal graft-versus-host disease after marrow transplantation. Gastrointest Endosc 1999;49:612-621.
26. Fallows G, Rubinger M, Bernstein CN. Does gastroenterology consultation change management of patients receiving hematopoietic stem cell transplantation? Bone Marrow Transplant 2001;28:289-294.